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Abstract
Background: Eczema herpeticum (EH) is a disseminated viral infection of eczematous skin 
disease with the herpes simplex virus. Knowledge on clinical characteristics, risk factors and 
recurrent disease is limited. Our aim was to better define clinical characteristics and risk 
factors for EH and especially for recurrent EH.
Methods: A retrospective analysis of EH cases assessed the history, clinical signs, prior 
treatment and laboratory results using a predefined questionnaire.
Results: A total of 224 EH cases from 8 European centers were included. Extrinsic AD was 
identified as risk factor for EH, only one patient suffered from intrinsic AD. Early-onset of AD 
was identified as risk factor for recurrent EH. Pre-treatment with topical steroids, systemic 
steroids, topical calcineurin inhibitors or plain emollients reflected standard therapy. Many 
patients showed AD lesions without EH, but skin without AD lesions was never affected by 
herpetic lesions.
Conclusion: Patients with clinically active, extrinsic AD are at risk for EH. Recurrent EH is 
associated with confounders of severe atopic distortion, and requires active AD lesions for 
clinical manifestation.  Recurrent eczema herpeticum mainly affects patients with early 
onset of AD.
Key words
Eczema herpeticum, atopic dermatitis, extrinsic, recurrence, distribution
Abbreviations
AD atopic dermatitis
CAP-FEIA CAP - fluoreszenz-enzyme-immunoassay
DNA desoxyribonucleic acid
EH eczema herpeticum
HSV herpes simplex virus
INF interferon
PCR polymerase chain reaction
RAST radio allergo sorbent testA
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Introduction
Eczema herpeticum is an acute, severe skin condition found in subjects with atopic 
dermatitis (AD). It presents with disseminated, monomorphic vesicles and can be 
accompanied by lymphadenopathy or fever (1).  Before the invention of acyclovir, the 
disease led to fatal outcomes with a mortality rate of up to 70% (2).  If EH is suspected in a 
patient, acyclovir or valcyclovir should be initiated immediately, since a delay can increase 
the length of hospitalization (3, 4).
Whilst AD is the most common chronic inflammatory skin disease, EH is a rare condition 
with an occurrence of 3% amongst a subset of AD patients (5). This suggests that certain risk 
factors influence the likelihood of developing EH. Multiple disadvantages of eczematous skin 
of AD subjects were associated with the uncontrolled replication of HSV in affected lesions. 
The disruption of cell junctions unmasks Nectin-1, enabling the virus to enter the cell (6, 7). 
The antiviral immune response in AD is deficient due to the lack of plasmacytoid dendritic 
cells, thus resulting in an insufficient IFN- γ production (8).  Defects in IFN- γ response are 
associated with a higher risk of viral skin infections (9). Furthermore, the AD-associated 
cathelicidin deficiency is a predisposing factor for EH (10). Recent data indicated an elevated 
type 2 response by virus specific T-cells may contribute to the higher susceptibility to viral 
infections (11). The majority of EH cases is caused by HSV-1 with F1 and F35 being the 
predominant genotypes according to a Japanese study (12).
Very few studies addressing the susceptibility of AD patients for EH have been performed on 
a larger number of EH cases (13-15). A high rate of skin infections with other microbes, a 
high total serum IgE and an early onset of AD were associated with the occurrence of EH (14, 
15). Several case reports indicate that multiple episodes of EH may occur in one patient (16-
19). 
We performed a retrospective analysis of 224 cases of EH, to identify novel clinical 
characteristics of EH, as well as risk factors of recurrent EH. 
MethodsA
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Study design and clinical data
This study is a retrospective analysis of 224 cases of EH seen over the course of 10 years by 
dermatological units at 8 European university hospitals. The diagnosis was made by a 
dermatologist and the data was then collected using a predefined questionnaire, which 
included the date of first EH symptoms, the date of EH diagnosis, concomitant diseases, list 
of medication, history of atopy, family history of atopy, date of diagnosis of AD, history of 
previous HSV infections, history of previous EH, history of recent exposition to HSV and 
meningeal or ocular involvement. 
Topical and systemic therapies of patients were assessed for up to 4 weeks before onset of 
EH to evaluate possible effects of AD treatment on EH.
Extrinsic vs. intrinsic AD subtypes
To differentiate between extrinsic and intrinsic AD, the patient’s history of atopy and the 
results of skin prick tests, total serum IgE levels, SX-1-CAP-FEIA and FX-5-CAP-FEIA were 
checked. AD was categorized according to Wüthrich as extrinsic if the patient presented one 
or several of the following features: elevated total serum IgE-levels ( 100 kU/l), positive 
results in standard skin prick tests, positive SX-1- or FX-5-CAP-FEIA, a history of allergic 
rhinoconjunctivits (RCA) or allergic bronchial asthma (20).
Scoring of AD Severity
Severity of AD was assessed by SCOring of Atopic Dermatitis (SCORAD) and Rajka-Langeland 
severity grading. The Rajka-Langeland score allows to distinguish between mild, moderate 
and severe AD by grading extent, course and intensity of the disease (21). The highest 
possible score is 9. The SCORAD permits to evaluate extent, severity and subjective 
symptoms (22). To assess the intensity; erythema, edema/ papulation, oozing/crusts, 
excoriations, lichenification and dryness are evaluated as separate subcategories. The 
highest possible score in this scoring system is 103. The areas affected by AD, as well as the 
areas affected by EH were estimated by hatching of predefined human body drawings.A
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Determination of primary vs. secondary HSV infection
Primary or secondary HSV infections were determined according to a predefined algorithm 
utilizing the patient’s history and serum levels of anti-HSV-IgM and –IgG antibodies, which 
were available in 69 cases (Fig. 1).
Statistical analysis
Mean values, minimum and maximum values, standard deviation and p-values were 
calculated using SPSS statistics software.
Results
Demographics of study population
224 cases of EH were included in the study, which had occurred in 214 patients. Gender 
distribution was almost equal with 122 male and 102 female patients. Patient’s mean age at 
onset of EH was 27,3 ± 11,9 years. The mean age of onset of the underlying AD was 9,5 ± 
10,1 years (n = 104).  Patients with recurrent EH were slightly but insignificantly older 
(median value 26 years) than those experiencing their first episode of EH (median value 24 
years). There was no significant age difference between patients with primary and patients 
with secondary HSV infection (19,83 ± 12,1 years vs. 26,57 ± 9,75 years). 
Long diagnostic period
It took on average 4,2 ± 3,4 days until patients were diagnosed with EH after realizing their 
first symptoms (Min 0 days, Max 21 days). Recurrent EH was diagnosed earlier (4,0 ± 2,69 
days) compared to first episodes of EH(4,4 ± 3,74 days), but the difference was not 
significant (p= 0,595).
Primary and secondary HSV infections may cause EH A
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Out of the 224 cases, 19 were clearly identified as primary HSV infection. In 112 cases EH 
was caused by a secondary HSV infection. Naturally, recurrent episodes of EH were assessed 
as secondary HSV infection. In 93 cases conclusive data was missing.
26,5 % EH recurrence rate
133 patients (n = 181) suffered from their first episode of EH, 17 patients endured the 
disease twice and 17 patients suffered from more than two episodes (Fig. 2). One patient 
endured seven episodes, which was the highest number of EH episodes in this study. The 
numbers add up to a recurrence rate of 26,5% (Fig. 2).
Recurrent EH is associated with early onset of AD
High disease severity of the underlying AD and an early age of AD onset have been identified 
as predisposing factors for EH in previous studies (14, 15). To check if those factors can be 
associated with recurrent EH, our study compared disease severity assessed by Rajka-
Langeland scores, SCORAD index, affected body surface area, as well as the age of AD onset 
in patients with one episode of EH to patients with multiple episodes of EH. EH patients in 
the study presented with a mean score of 6,34 ± 1,77 in Rajka-Langeland Score and 44,21 ± 
18,17 in SCORAD (n=89). Patients with a single episode of EH presented with a mean 
SCORAD of 42,28 and a mean affected body surface area of 34,4%. Patients with multiple 
episodes of EH showed mean SCORAD levels of 46,12 and 44,6% affected body surface area. 
Both parameters were slightly, but insignificantly higher in patients with recurrent AD.
The comparison of age of onset showed that patients with recurrent EH were significantly 
younger at onset of the underlying AD (5,43 ± 12,9 years of age) opposed to patients with 
just a single EH episode (11,1 ± 6,5 years of age) (p = 0,016, n = 104) (Fig. 3 and Fig. 4a). 
Allergological characteristics of EH patients
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In our patient cohort, 66,1 % reported a history of RCA, 37,5 % reported a history of asthma. 
The average serum total IgE-level was 976,64 kU/l, with a minimum of 17 kU/l and a 
maximum of 37940 kU/l (n=102). There was no significant difference in serum IgE-levels of 
patients with one episode of EH opposed to patients with multiple episodes (Fig. 4b).
Extrinsic AD is a risk factor for EH 
According to the criteria named above, 184 cases of EH occurred in patients with extrinsic 
AD. Only one patient in the study presented with an intrinsic form of AD. The difference was 
statistically highly significant (p < 0,001, n = 185). Conclusive data regarding the 
extrinsic/intrinsic status was missing in 39 cases.
Prior treatment has no influence on EH development 
Both topical treatment and systemic treatment used up to 4 weeks prior to onset of EH were 
analyzed.  76 patients had used at least once topical steroids, 15 at least once tacrolimus 
ointment and 5 pimecrolimus cream at least once in the last 4 weeks before onset of EH. 
However, 23 patient had exclusively used emollients and 32 patients had not received any 
topical treatment at all (n = 151) (Fig. 5a). This adds up to 55 patients, who did not receive 
any topical anti-inflammatory treatment prior to the EH.
118 patients did not receive any systemic treatment prior to their EH, 10 patients received 
systemic corticosteroids, 2 received cyclosporine A and 1 patient received both 
corticosteroids and cyclosporine A in the last 4 weeks prior to onset of their EH (n = 131) 
(Fig. 5b).
Herpetic lesions are restricted to body areas affected by visible AD lesions
The distribution of EH lesions and AD lesions was assessed by two different methods: 
shading of body drawings and explicit questions for the presence of AD areas without 
herpetic lesions, as well as herpetic lesions outside of the areas of AD. EH lesions were only 
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found in areas previously affected by the underlying AD. EH lesions did not appear in non-
lesional skin regions (n=126). The information was not available to us in all of the 224 cases.
Discussion
This multicenter study was performed to reveal further information about the clinical 
characteristics and risk factors of EH in general and especially of recurrent EH. Extrinsic AD 
displayed the main risk factor for EH. Early-onset of AD was identified as risk factor for 
recurrent EH. Pre-treatment with topical steroids, systemic steroids, topical calcineurin 
inhibitors or emollients reflected standard therapy (23). Skin without AD lesions was never 
affected by herpetic lesions. Four larger retrospective studies on EH have been published so 
far, our study represents the largest number of cases and is the only study that highlights 
risk factors for EH recurrence (13-15, 24). 
The recurrence rate of EH was 26,5% in our study. The rate seems to vary drastically 
between studies. Previous studies noted rates of recurrence between 12% - 50% (13-15, 
24).  
A Canadian study including 79 patients indicated that hospitalized patients have an 
increased risk of EH recurrence (24). Since EH is a rare disease, there are no distinct and 
validated criteria as to when a patient should be hospitalized. Therefore, hospitalization is 
usually a discretionary decision of the treating physician. It is common sense that hospital 
admissions are more likely to occur in severe cases. Thus, defining further risk factors 
besides hospitalization seems crucial.
An early onset of the underlying AD is associated with more severe disease and a known risk 
factor for EH (15). In our study, patients with recurrent EH were significantly younger at AD 
onset than patients with just a single episode of EH. This is a novel finding, as it has never 
been assessed in larger studies. Our results implicate that an early age of AD onset not only 
predisposes to EH manifestation, but also to EH recurrences.
A remarkable finding was the significantly higher number (n=189) of patients with extrinsic 
AD opposed to only one patient with intrinsic AD. This suggests a correlation between the 
atopic distortion of the patient and the disposition to EH occurrence. The rate of patients 
with intrinsic AD is usually about 10 - 40% according to larger studies (20, 25-27). A A
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previous study showed that patients with extrinsic AD tend to have a more severe, 
refractory type of AD opposed to patients without signs of atopy (28). It has been reported 
that AD patients with a positive history for food allergies or asthma are more likely to 
develop EH, which further supports this hypothesis (14). 
The mean total IgE-level in our patients was 976,64 U/ml, the majority ranging between 
1000 and 9999 U/ml (Fig. 4b). High IgE-levels have been associated with EH previously (15, 
29).  However, our study did not see a correlation between high IgE-levels and EH 
recurrence. A greater TH2 polarity may explain the higher IgE levels in extrinsic AD.  In 
addition, extrinsic and intrinsic AD patients show different cytokine activation patterns (30).  
Cytokines secreted by TH2-cells can induce apoptosis of plasmacytoid dendritic cells (30). A 
lack of these cells leads to a deficient IFN- γ production and results in a higher susceptibility 
to viral infections (8). This idea is endorsed by a study, which demonstrated high IgE-levels, 
but low IFN-γ levels in patients with EH (29). The importance of TH2-cells in EH 
development is also reflected in our finding, that an early onset of AD is a risk factor for EH. 
Patients with early-onset of AD present very low TH1 cell activation, but excessive 
production of TH2 cells (30).  Recent data supports the theory that the TH2 response largely 
contributes to the pathology of EH (11).  An elevated Type 2 cell response to HSV was found 
in AD patients.
With a mean SCORAD of 44,2 and a mean Rajka-Langeland Score of 6,34, our study supports 
the hypothesis that patients with moderate to severe AD are more likely to develop EH (14). 
However, there was no significant difference in disease severity between patients with one 
episode of EH and patients with recurrent EH. To further evaluate the role of disease 
severity in recurrence of EH, long term follow-ups of patients with EH would be needed. 
Currently, we cannot clearly state if patients were spared from recurrence due to 
improvement of skin lesions or for other reasons.
Besides the missing data on long term follow-ups of the patients, the dataset was not 
complete for all readouts. This was due to the retrospective design of the study. Because of 
the large number of cases, we were still able to detect valuable information on EH and its 
risk factors.
Some authors discussed an association of EH with the use of topical steroids or topical 
calcineurin inhibitors (13, 18). Other authors assumed that the use of corticosteroids does A
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not seem to impact EH manifestation (15, 31). Our results support the assumption that there 
is no correlation between EH occurrence and the previously used AD treatment, as most 
patients had not received any systemic treatment prior to the event and 55 patients had not 
received a topical anti-inflammatory treatment. Untreated AD lesions may actually be more 
prone to EH, considering that severe AD has been identified as risk factor for EH (14). 
Topical steroids or calcineurin inhibitors may even be used to treat the underlying AD in 
patients with EH.  A study showed that the use of such treatments is not associated with a 
poorer outcome of EH (32). To the contrary, the discontinuation of topical corticosteroids 
may actually contribute to the outbreak of EH. This was associated with elevation of 
regulatory T cells and proinflammatory monocytes after the withdrawal of corticosteroids 
(33).
The number of male patients was slightly higher in our study than that of female patients. 
Male predominance has been described for EH in a study including 50 Korean children and 
was therefore defined as risk factor for EH (34). Other large-scale studies showed an 
insignificant female predominance (14, 15, 35). Taken together, gender is most probably not 
a risk factor for EH.
It took an average of 4 days until the patients in our study were diagnosed with EH. This 
delay of diagnosis and treatment has not been addressed in any larger study before. The 
time frame seems unacceptably long, considering the high mortality of untreated 
disseminated HSV infections (2). Delayed initiation of acyclovir is associated with an 
increased length of stay of hospitalized EH patients and just recently a lethal case of EH has 
been reported (3, 36).  Therefore, immediate diagnosis and treatment initiation are crucial. 
Our patients with recurrent EH were diagnosed a little sooner, but not significantly. It could 
be expected that patients having ever experienced an episode of EH would seek medical help 
and treatment sooner because they know what to expect in the next days, but this was not 
the case.
The morphology of the vesicles in EH has been described multiple times, but information 
about the distribution pattern was lacking (14, 15, 37). This study was able to demonstrate 
that EH lesions will only affect lesional AD skin. Areas of the skin that do not show signs of 
eczema will be spared from the characteristic vesicular eruption. This was true in all 126 
cases of EH in this study, where distribution was documented. Conclusively, the spread of EH A
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lesions is limited by the distribution pattern of the underlying AD. This information can help 
to differentiate EH from other skin conditions and will hopefully lead to a faster diagnosis of 
affected patients. 
Clinical Implications
EH occurs almost exclusively in extrinsic AD patients. An early onset of AD is associated with 
the development of EH, and in addition a predisposing factor of recurrent EH. The spread of 
EH lesions is limited by the distribution of the underlying AD. 
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